-transparent.png){kind=logo}
The combination of Epstein-Barr-Virus (EBV)-permitted immortalization and somatic hybridization (fusion with a myeloma partner) may be the method of choice to produce human monoclonal antibodies. We show here that the fusion of EBV-infected human B-lymphocytes to the HAT-sensitive, ouabain-resistent heteromyeloma (human x mouse) fusion line CB-F7, resulted in stable growing hybridomas producing much more immunoglobulin than the parental lymphoblastoid lines. A more efficient clonability was shown for hybridoma cultures too. The loss of B cell markers (HLA-class II antigen, CD-22, CD-37) was detected. Limiting dilution experiments showed a better fusionability of IgM-producing EBV-transformed B cells in comparison to IgG-secreting counterparts.
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
April 2000,
Oncogene,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
January 1986,
Current topics in microbiology and immunology,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
January 1989,
Annual review of immunology,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
March 1976,
Cell differentiation,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
January 2012,
PloS one,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
January 2004,
Oncology research,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
January 1984,
Nature,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
February 1984,
Journal of immunology (Baltimore, Md. : 1950),
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
February 2007,
Current protocols in immunology,
S Jahn, and
A Walper, and
R Grunow, and
S Heym, and
H D Volk, and
R von Baehr
November 2013,
BMC genomics,
